Myriad Genetics announces survey results on depression, anxiety

Nearly nine out of ten Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half from taking medication, according to the latest GeneSight Mental Health Monitor, a nationwide survey from Myriad Genetics (MYGN). The majority of these patients agree that genetic testing for mental health medications could reduce these concerns. Among those diagnosed with depression and/or anxiety, 62% of patients whose healthcare provider did not use PGx testing wish they had been informed about it. The GeneSight Mental Health Monitor also revealed: 67% of Americans surveyed strongly agree that it is socially acceptable to take medications for mental health; 62% of Americans surveyed strongly agree that they would feel comfortable discussing their use of mental health medications with their family; 66% of Americans surveyed have a positive view of other people taking mental health medications, with just 5% reporting a negative view. In fact, respondents rated the effectiveness of mental health medications as similar to that of medications prescribed for their high blood pressure, high cholesterol, and arthritis.